NCT00555724View on ClinicalTrials.gov

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

July 31, 2010

Conditions

Solid Tumors

Interventions

DRUG

BIIB022

IV infusion once every three weeks until disease progression or unacceptable toxicity

Trial Locations (3)

Unknown

Research Site, Los Angeles

Research Site, Aurora

Research Site, Philadelphia

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Biogen

INDUSTRY